CoChat

RETRACTED ARTICLE: Piperlongumine inhibits lung tumor growth via inhibition of nuclear factor kappa B signaling pathway

Open access
Zheng, Jie, Son, Dong Ju, Gu, Sun Mi, Woo, Ju Rang, Ham, Young Wan, Lee, Hee Pom, Kim, Wun Jae, Jung, Jae Kyung, Hong, Jin Tae · 2016 · Scientific Reports
Cited by 92

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Piperlongumine has anti-cancer activity in numerous cancer cell lines via various signaling pathways. But there has been no study regarding the mechanisms of PL on the lung cancer yet. Thus, we evaluated the anti-cancer effects and possible mechanisms of PL on non-small cell lung cancer (NSCLC) cells in vivo and in vitro. Our findings showed that PL induced apoptotic cell death and suppressed the DNA binding activity of NF-κB in a concentration dependent manner (0–15 μM) in NSCLC cells. Docking model and pull down assay showed that PL directly binds to the DNA binding site of nuclear factor-κB (NF-κB) p50 subunit, and surface plasmon resonance (SPR) analysis showed that PL binds to p50 concentration-dependently. Moreover, co-treatment of PL with NF-κB inhibitor phenylarsine oxide (0.1 μM) or p50 siRNA (100 nM) augmented PL-induced inhibitory effect on cell growth and activation of Fas and DR4. Notably, co-treatment of PL with p50 mutant plasmid (C62S) partially abolished PL-induced cell growth inhibition and decreased the enhanced expression of Fas and DR4. In xenograft mice model, PL (2.5–5 mg/kg) suppressed tumor growth of NSCLC dose-dependently. Therefore, these results indicated that PL could inhibit lung cancer cell growth via inhibition of NF-κB signaling pathway in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep26357This paper is marked retracted.

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 30

  1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9–29 (2014). · DOI · Paper page
  2. Thomas, A., Chen, Y., Yu, T., Jakopovic, M. & Giaccone, G. Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States. Front Oncol 5, 113 (2015). · DOI
  3. Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E. & Adjei, A. A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83, 584–594 (2008). · DOI · Paper page
  4. Karin, M. & Greten, F. R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5, 749–759 (2005). · DOI · Paper page
  5. Jin, X. et al. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci 99, 582–589 (2008). · doi:10.1111/j.1349-7006.2007.00713.x
  6. Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2, 301–310 (2002). · DOI · Paper page
  7. Tsao, S. M., Hsia, T. C. & Yin, M. C. Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-kappaB pathways. Nutr Cancer 66, 1331–1341 (2014). · doi:10.1080/01635581.2014.956259
  8. Choi, K. E. et al. Cancer cell growth inhibitory effect of bee venom via increase of death receptor 3 expression and inactivation of NF-kappa B in NSCLC cells. Toxins (Basel) 6, 2210–2228 (2014). · DOI
  9. Ban, J. O. et al. Thiacremonone augments chemotherapeutic agent-induced growth inhibition in human colon cancer cells through inactivation of nuclear factor-{kappa}B. Mol Cancer Res 7, 870–879 (2009). · DOI
  10. Kollipara, P. S., Jeong, H. S., Han, S. B. & Hong, J. T. (E)-2,4-bis (p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-kappaB and up-regulation of TNFRSF10B (DR5). Br J Pharmacol 168, 1471–1484 (2013). · DOI
  11. Chatterjee, A. & Dutta, C. P. Alkaloids of Piper longum Linn. I. Structure and synthesis of piperlongumine and piperlonguminine. Tetrahedron 23, 1769–1781 (1967). · DOI
  12. Raj, L. et al. Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475, 231–234 (2011). · DOI · Paper page
  13. Golovine, K. et al. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther 16, 743–749 (2015). · DOI
  14. Roh, J. L. et al. Piperlongumine selectively kills cancer cells and increases cisplatin antitumor activity in head and neck cancer. Oncotarget 5, 9227–9238 (2014). · DOI
  15. Dhillon, H., Chikara, S. & Reindl, K. M. Piperlongumine induces pancreatic cancer cell death by enhancing reactive oxygen species and DNA damage. Toxicol Rep 1, 309–318 (2014). · DOI
  16. Bharadwaj, U. et al. Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. Oncogene 34, 1341–1353 (2015). · DOI · Paper page
  17. Gong, L. H. et al. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev 2014, 906804 (2014). · DOI
  18. Ginzburg, S. et al. Piperlongumine inhibits NF-kappaB activity and attenuates aggressive growth characteristics of prostate cancer cells. Prostate 74, 177–186 (2014). · DOI
  19. Randhawa, H., Kibble, K., Zeng, H., Moyer, M. P. & Reindl, K. M. Activation of ERK signaling and induction of colon cancer cell death by piperlongumine. Toxicol In Vitro 27, 1626–1633 (2013). · DOI
  20. Wessel, M. D., Jurs, P. C., Tolan, J. W. & Muskal, S. M. Prediction of human intestinal absorption of drug compounds from molecular structure. J Chem Inf Comput Sci 38, 726–735 (1998). · DOI · Paper page
  21. Elrod, H. A. & Sun, S. Y. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 7, 163–173 (2008). · DOI
  22. Choi, K. E. et al. Myriocin induces apoptotic lung cancer cell death via activation of DR4 pathway. Arch Pharm Res 37, 501–511 (2014). · DOI
  23. Ban, J. O. et al. Enhanced cell growth inhibition by thiacremonone in paclitaxel-treated lung cancer cells. Arch Pharm Res 38, 1351–1362 (2015). · doi:10.1007/s12272-015-0589-4
  24. Park, M. H. et al. Anticancer effect of tectochrysin in colon cancer cell via suppression of NF-kappaB activity and enhancement of death receptor expression. Mol Cancer 14, 124 (2015). · DOI
  25. Ban, J. O. et al. (E)-2,4-Bis (p-hydroxyphenyl)-2-butenal inhibits tumor growth via suppression of NF-kappaB and induction of death receptor 6. Apoptosis 19, 165–178 (2014). · DOI
  26. Zheng, J. et al. (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol inhibits growth of colon tumors in mice. Oncotarget 6, 41929–41943 (2015). · DOI
  27. Zheng, J. et al. Anti-cancer effect of bee venom on colon cancer cell growth by activation of death receptors and inhibition of nuclear factor kappa B. Oncotarget 10.18632/oncotarget.6295 (2015). · DOI
  28. Liu, F. et al. NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 287, 25530–25540 (2012). · DOI
  29. Chen, F., Castranova, V. & Shi, X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am J Pathol 159, 387–397 (2001). · DOI · Paper page
  30. Nakanishi, C. & Toi, M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5, 297–309 (2005). · DOI · Paper page

Cited by

Metadata

Authors
Zheng, J., Son, D. J., Gu, S. M., Woo, J. R., Ham, Y. W., Lee, H. P., Kim, W. J., Jung, J. K., & Hong, J. T.
Venue
Scientific Reports
Published
2016-05-20
Volume
6
Issue
1
Pages
26357-26357
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2403949460
Cited by
92
References
4
FWCI
10.74
Type
journal article
Language
en
Status
Retracted
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.